Learning the language of life
AI is discovering new drugs. Sound like science fiction? Not at Absci! Sean and Joshua join us to discuss their AI-driven pipeline for drug discovery. We discuss the tech along with how it might change how we think about healthcare at the most fundamental level.
Sponsors:
Changelog++ – You love our content and you want to take it to the next level by showing your support. We’ll take you closer to the metal with extended episodes, make the ads disappear, and increment your audio quality with higher bitrate mp3s. Let’s do this!
Featuring:
Sean McClain – LinkedIn, X
Joshua Meier – GitHub, LinkedIn, X
Chris Benson – Website, GitHub, LinkedIn, X
Daniel Whitenack – Website, GitHub, X
Show Notes:
View Absci’s AI Lead Scientist Joshua Meier’s presentation at NVIDIA GTC 2022
Learn more about Absci’s machine learning breakthroughs presented at GTC
Learn more about Absci AI Research (AAIR) Lab
View career opportunities at Absci
Absci AI drug discovery technology
Watch the Truist AI Symposium Podcast to get help demystifying the use of AI in drug discovery
Absci website
Upcoming Events:
Register for upcoming webinars here!
Sean & Greg — Biology and ML for Drug Discovery
Sean McClain is the founder and CEO, and Gregory Hannum is the VP of AI Research at Absci, a biotech company that's using deep learning to expedite drug discovery and development.
Lukas, Sean, and Greg talk about why Absci started investing so heavily in ML research (it all comes back to the data), what it'll take to build the GPT-3 of DNA, and where the future of pharma is headed. Sean and Greg also share some of the challenges of building cross-functional teams and combining two highly specialized fields like biology and ML.
The complete show notes (transcript and links) can be found here: http://wandb.me/gd-sean-and-greg
---
Connect with Sean and Greg:
📍 Sean's Twitter: https://twitter.com/seanrmcclain
📍 Greg's Twitter: https://twitter.com/gregory_hannum
📍 Absci's Twitter: https://twitter.com/abscibio
---
Timestamps:
0:00 Intro
0:53 How Absci merges biology and AI
11:24 Why Absci started investing in ML
19:00 Creating the GPT-3 of DNA
25:34 Investing in data collection and in ML teams
33:14 Clinical trials and Absci's revenue structure
38:17 Combining knowledge from different domains
45:22 The potential of multitask learning
50:43 Why biological data is tricky to work with
55:00 Outro
---
Subscribe and listen to our podcast today!
👉 Apple Podcasts: http://wandb.me/apple-podcasts
👉 Google Podcasts: http://wandb.me/google-podcasts
👉 Spotify: http://wandb.me/spotify